Jun 03, 2017 4:00pm EDT Matinas BioPharma Announces Interim Data from NIH-Conducted Phase 2a Clinical Study of Orally-Administered MAT2203 for the Treatment of Chronic Refractory Mucocutaneous Candidiasis
Jun 02, 2017 4:01pm EDT Matinas BioPharma Presents Positive Preclinical Efficacy Data of MAT2203 in Mouse Model of Cryptococcal Meningoencephalitis
Jun 01, 2017 7:05am EDT Matinas BioPharma to Present at the 2017 Jefferies Global Healthcare Conference
May 30, 2017 8:05am EDT Matinas BioPharma Announces Two Upcoming Data Presentations of Lead Product Candidate MAT2203 at The American Society for Microbiology’s ASM Microbe 2017 Conference
May 16, 2017 7:05am EDT Matinas BioPharma Reports 2017 First Quarter Financial Results and Provides Corporate Update
Apr 24, 2017 7:00am EDT Matinas BioPharma Presents Positive Preclinical Data of Orally Available DNA Vaccines at the 27th Annual European Congress of Clinical Microbiology and Infectious Diseases
Apr 18, 2017 7:01am EDT Matinas BioPharma Appoints Dominick DiPaolo as Senior Vice President of Quality and Regulatory Compliance
Apr 03, 2017 7:06am EDT Matinas BioPharma Reports 2016 Financial Results and Provides Corporate Update
Mar 30, 2017 7:05am EDT Matinas BioPharma Appoints Eric J. Ende, M.B.A, M.D. to its Board of Directors
